Guardant Health Inc. (GH)
Exploring Analyst Estimates for Guardant Health (GH) Q4 Earnings, Beyond Revenue and EPS
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Guardant Health (GH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.
Guardant Health (GH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Guardant Health: Asymptomatic Screening Creating An Asymmetric Opportunity
Blood-based cancer testing presents a large opportunity, that is now being realized, with the proliferation of MRD and screening tests. While there is significant competition, and the market winners are yet to be determined, Guardant Health is well positioned. Guardant has faced skepticism due to its large losses and the questionable efficacy of blood-based CRC screening tests.
Here's Why Guardant Health (GH) Is a Great 'Buy the Bottom' Stock Now
After losing some value lately, a hammer chart pattern has been formed for Guardant Health (GH), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Are Medical Stocks Lagging Guardant Health (GH) This Year?
Here is how Guardant Health (GH) and Alnylam Pharmaceuticals (ALNY) have performed compared to their sector so far this year.
Guardant Health Gains Medicare Coverage For Colorectal Cancer Monitoring Test
On Tuesday, Guardant Health, Inc. GH announced that Palmetto GBA, a Medicare administrative contractor that administers the Molecular Diagnostics Services program (MolDX), granted coverage for the Guardant Reveal test to monitor for disease recurrence in patients with colorectal cancer (CRC) following curative intent therapy.
Why Top 4% Guardant Health Surged To A 13-Month High And Topped A Profit-Taking Zone
Guardant Health stock hit a 13-month high Tuesday after Medicare officials agreed to pay for the company's colon cancer blood test. The post Why Top 4% Guardant Health Surged To A 13-Month High And Topped A Profit-Taking Zone appeared first on Investor's Business Daily.
Guardant Health (GH) Soars 6.3%: Is Further Upside Left in the Stock?
Guardant Health (GH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Guardant Health Stock Flashing Surefire ‘Buy' Signal
Biotechnology stock Guardant Health (GH) is trading at 15-month highs today, last seen up 7% at $38.28. Shares have added 107.7% over the last nine months, and now stand nearly 42% higher in 2024.
Guardant Health, Inc. (GH) Q3 2024 Earnings Call Transcript
Guardant Health, Inc. (GH) Q3 2024 Earnings Call Transcript
Guardant Health (GH) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Guardant Health (GH) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates
Guardant Health (GH) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.73 per share a year ago.
